US Patent Issued to Specific Biologics on Nov. 4 for "Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing" (Canadian Inventors)

ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,460,192, issued on Nov. 4, was assigned to Specific Biologics Inc. (Canada).

"Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing" was invented by David R. Edgell (Toronto), Thomas A. McMurrough (Toronto), Brent E. Stead (Toronto) and Odisho K. Israel (Toronto).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are methods to edit genes, for example by administering a chimeric nuclease to a cell or organism without the use of a viral vector. Some methods herein include editing DNA of a cell by contacting the cell with a nuclease comprising a Cas9 sequence, where the nuclease edits the DNA of the cell."

The patent was filed...